natgillin/translations-raw huggingface dataset:
100 mg mellem 30 og 40 kg 
100 milligram between 30 and 40 kilograms 675 milligram
ART-erfarne pædiatriske patienter (3 til 17 år og legemsvægt mindst 40 kg) Hos ART-erfarne patienter, der ikke har DRV-RAMs*, og som har plasma-hiv-1 
ART-experienced paediatric patients (3 to 17 years of age and weighing at least 40 kg) In ART-experienced patients without DRV-RAMs* and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10
- Øvrige indholdsstoffer: mikrokrystallinsk cellulose, crospovidon, hydroxypropylcellulose, silica, kolloid vandfri, silicificeret mikrokrystallinsk cellulose (mikrokrystallinsk cellulose; silica, kolloid vandfri) og magnesiumstearat (E470b) i tabletkernen og polyvinylalkohol, macrogol, titandioxid (E171), talcum (E553b), jernoxid, gul (E172) og jernoxid, rød (E172) i filmovertrækket. 
silica, colloidal anhydrous ) and magnesium stearate (E470b)in the tablet core and poly(vinyl alcohol), macrogol, titanium dioxide (E171), talc (E553b), yellow iron oxide (E172) and red iron oxide (E172) in film coating.
Darunavir Krka 800 mg filmovertrukne tabletter darunavir 
Darunavir Krka 800 mg film-coated tablets darunavir
Darunavir Krka 400 mg filmovertrukne tabletter darunavir 
Darunavir Krka 400 mg film-coated tablets darunavir
Carbamazepin AUC ↑ 45% Carbamazepin Cmin ↑ 54% Carbamazepin Cmax ↑ 43% darunavir AUC ↔ darunavir Cmin ↓ 15% darunavir Cmax ↔ 
Carbamazepine 200 mg twice daily carbamazepine AUC ↑ 45% carbamazepine Cmin ↑ 54% carbamazepine Cmax ↑ 43% darunavir AUC ↔ darunavir Cmin ↓ 15% darunavir Cmax ↔
Samtidig administration af darunavir med lavdosis ritonavir og alfuzosin er kontraindiceret (se pkt. 
Co-administration of darunavir with low dose ritonavir and alfuzosin is contraindicated (see section 4.3).
Andet trimester af graviditeten (n=12) 
Second trimester of pregnancy (n=12)
Darunavir/ ritonavir 800/100 mg en gang dagligt N=294 
darunavir/ ritonavir 800/100 mg once daily N=294
Ved 48-ugers-analysen blev non-inferioritet i virologisk respons over for darunavir/ritonavir behandlingen, defineret som procentdelen af patienter med plasma hiv-1-RNA niveau < 50 kopier/ml, blev påvist (ved den forud definerede 12 % noninferioritetsgrænse) hos begge populationer (”Intent-To-Treat” og ”On Protocol”). 
Non-inferiority in virologic response to the darunavir/ritonavir treatment, defined as the percentage of patients with plasma HIV-1 RNA level < 50 copies/ml, was demonstrated (at the pre-defined 12% non-inferiority margin) for both Intent-To-Treat (ITT) and On Protocol (OP) populations in the 48 week analysis.
Det skal du vide, før du begynder at tage Darunavir Krka Sådan skal du tage Darunavir Krka Bivirkninger 
What Darunavir Krka is and what it is used for What you need to know before you take Darunavir Krka How to take Darunavir Krka Possible side effects
Den samlede farmakokinetiske, forstærkende effekt af ritonavir medførte en ca. 14fold stigning i den systemiske eksponering for darunavir ved administration af en oral enkeltdosis darunavir på 600 mg i kombination med 100 mg ritonavir to gange daglig (se pkt. 
The overall pharmacokinetic enhancement effect by ritonavir was an approximate 14-fold increase in the systemic exposure of darunavir when a single dose of 600 mg darunavir was given orally in combination with ritonavir at 100 mg twice daily (see section 4.4).
Klinisk monitorering anbefales, når boostet darunavir administreres sammen med lavdosis ritonavir og clonazepam. 
Clinical monitoring is recommended when co-administering boosted darunavir and clonazepam.
Darunavir Krka 400 og 800 mg tabletter anvendes kun til at sammensætte en daglig dosis på 800 mg. 
Darunavir Krka 400 and 800 milligram tablets are only to be used to construct the once daily 800 milligram regimen.
De farmakokinetiske egenskaber af darunavir i kombination med ritonavir en gang daglig hos 12 ART-naive pædiatriske patienter i alderen 12 til <18 år med en legemsvægt på mindst 40 kg viste, at darunavir/ritonavir 800/100 mg en gang daglig resulterede i en darunavireksponering, der var sammenlignelig med eksponeringen hos voksne, der fik darunavir/ritonavir 800/100 mg en gang daglig. 
The pharmacokinetics of darunavir in combination with ritonavir taken once daily in 12 ART-naïve paediatric patients, aged 12 to < 18 years and weighing at least 40 kg, showed that darunavir/ritonavir 800/100 mg once daily results in darunavir exposure that was comparable to that achieved in adults receiving darunavir/ritonavir 800/100 mg once daily.
Sådan skal du tage Darunavir Krka 
How to take Darunavir Krka
675 mg darunavir/100 mg ritonavir en gang dagligt 
675 mg darunavir/100 mg ritonavir once daily
Darunavir/ritonavir 800/100 mg en gang dagligt hos ART-erfarne patienter bør ikke anvendes til patienter med en eller flere mutationer associeret med darunavirresistens (DRV-RAMs) eller hiv-1 RNA ≥ 100.000 kopier/ml eller CD4+-celletal < 100 x 10 celler/l (se pkt. 
Darunavir/ritonavir 800/100 mg once daily in ART-experienced patients should not be used in patients with one or more darunavir resistance associated mutations (DRV-RAMs) or HIV-1 RNA ≥ 100,000 copies/ml or CD4+ cell count < 100 cells x 10
7,7% af den administrerede dosis darunavir udskilles uomdannet i urinen. 
C-darunavir with ritonavir showed that approximately 7.7% of the administered dose of darunavir is excreted in the urine unchanged.
Det frarådes at co-administrere darunavir med lavdosis ritonavir simeprevir. 
It is not recommended to coadminister darunavir with low dose ritonavir and simeprevir.
Boostet darunavir og raltegravir kan administreres uden dosisjusteringer. 
Boosted darunavir and raltegravir can be used without dose adjustments.
DIONE er et åbent fase II-studie til evaluering af farmakokinetik, sikkerhed, tolerabilitet og effekt af darunavir sammen med lavdosis ritonavir hos 12 ART-naive hiv-1-smittede pædiatriske patienter i alderen 12 år til < 18 år med en legemsvægt på mindst 40 kg. 
ART-naïve paediatric patients from the age of 12 years to < 18 years, and weighing at least 40 kg DIONE is an open-label, Phase II trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of darunavir with low dose ritonavir in 12 ART-naïve HIV-1 infected paediatric patients aged 12 to less than 18 years and weighing at least 40 kg.
For patienter, der får kombinationsbehandling med darunavir co-administreret med ritonavir, er det nødvendigt at reducere dosis af rifabutin med 75% af den sædvanlige dosis på 300 mg/dag (f.eks. rifabutin 150 mg hver anden dag) samt en skærpelse i overvågningen af rifabutinrelaterede bivirkninger. 
A dosage reduction of rifabutin by 75% of the usual dose of 300 mg/day (i.e. rifabutin 150 mg once every other day) and increased monitoring for rifabutin related adverse events is warranted in patients receiving the combination with darunavir co-administered with ritonavir.
Dosis til børn fra 3 år og opefter med en legemsvægt på mindst 40 kg, som tidligere har fået medicin mod hiv-infektion (barnets læge vil afgøre dette) 
Dose for children 3 years of age and above, weighing more than 40 kilograms who have taken antiretroviral medicines before (your child's doctor will determine this) The dose is either:
Perikon forventes at nedsætte plasmakoncentrationen af darunavir eller dets farmakoforstærkere. 
St John's wort is expected to decrease the plasma concentrations of darunavir or its pharmacoenhancers.
Boostet darunavir og dolutegravir kan bruges uden dosisjustering. 
Boosted darunavir and dolutegravir can be used without dose adjustment.
hævelser i ansigt eller lymfekirtler, øgning i antallet af eosinofile celler (en type hvide blodlegemer), påvirkning af lever, nyrer eller lunger] - hjerteanfald, langsom puls, hjertebanken - synsforstyrrelser - kulderystelser, unormal følelse - følelse af forvirring eller desorientering, humørændring, rastløshed - besvimelse, epileptiske anfald, ændring i eller tab af smagsoplevelse - mundsår, opkastning af blod, betændelse i læberne, tørre læber, belagt tunge - snue - beskadigelse af huden, tør hud - stive muskler eller led, ledsmerter med eller uden betændelse - ændringer i visse blodlegemer eller i blodets kemiske sammensætning. 
Rare side effects (may affect up to 1 in 1,000 people) areaction called DRESS [severe rash, which may be accompanied by fever, fatigue, swelling of the face or lymph glands, increase of eosinophils (type of white blood cells), effects on liver, kidney or lung] heart attack, slow heart beating, palpitations visual disturbance chills, feeling abnormal a feeling of confusion or disorientation, altered mood, restlessness fainting, epileptic fits, changes or loss of taste mouth sores, vomiting blood, inflamation of the lips, dry lips, coated tongue running nose skin lesions, dry skin stiffness of muscles or joints, joint pain with or without inflammation changes in some values of your blood cells or chemistry.
Darunavir/ ritonavir 600/100 mg to gange dagligt N=298 
darunavir/ ritonavir 600/100 mg twice daily N=298
Klinisk monitorering anbefales ved co-administration af darunavir med betablokkere. 
Clinical monitoring is recommended when co-administering boosted darunavir with β-blockers.
Hver filmovertrukken tablet indeholder 600 mg darunavir. 
Each film-coated tablet contains 600 mg darunavir.
800 mg darunavir/100 mg ritonavir en gang dagligt 
800 mg darunavir /100 mg ritonavir once daily
Orangebrune, ovale, bikonvekse filmovertrukne tabletter indgraveret med mærket S2 på den ene side. 
Orangish brown, oval, biconvex film-coated tablets, engraved with a mark S2 on one side.
Dosis til børn fra 3 år og opefter med en legemsvægt på mindst 40 kg, som ikke tidligere har fået medicin mod hiv-infektion (barnets læge vil afgøre dette) - Den sædvanlige dosis af Darunavir Krka er 800 mg (2 tabletter a 400 mg 
Dose for children 3 years of age and above, weighing more than 40 kilograms who have not taken antiretroviral medicines before (your child's doctor will determine this) The usual dose of Darunavir Krka is 800 milligram (2 tablets containing 400 milligram of Darunavir Krka or 1 tablet containing 800 milligram of Darunavir Krka) together with 100 milligram ritonavir once daily.
Klinisk monitorering af terapeutiske og uønskede virkninger anbefales, når disse lægemidler administreres sammen med boostet darunavir. 
Clinical monitoring of therapeutic and adverse effects is recommended when these medicines are
6 celler/l (se pkt. 
6/l (see section 4.2).
Hver filmovertrukken tablet indeholder 400 mg darunavir. 
Each film-coated tablet contains 400 mg darunavir.
Darunavir/ritonavir 600/100 mg x 2 + OBR N=296 
darunavir/ritonavir 600/100 mg twice daily + OBR N=296
30 filmovertrukne tabletter: EU/1/17/1249/001 60 filmovertrukne tabletter: EU/1/17/1249/002 90 filmovertrukne tabletter: EU/1/17/1249/003 180 filmovertrukne tabletter: EU/1/17/1249/004 
30 film-coated tablets: EU/1/17/1249/001 60 film-coated tablets: EU/1/17/1249/002 90 film-coated tablets: EU/1/17/1249/003 180 film-coated tablets: EU/1/17/1249/004
(DRV-RAMs)*, og som har plasma hiv-1-RNA < 100.000 kopier/ml og CD4+ 
In ART-experienced patients without DRV-RAMs* and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10
Darunavir Krka 400 mg filmovertrukne tabletter Darunavir Krka 800 mg filmovertrukne tabletter darunavir 
Darunavir Krka 400 mg film-coated tablets Darunavir Krka 800 mg film-coated tablets darunavir
Darunavir anvendt i kombination med cobicistat eller lavdosis ritonavir en gang daglig hos ART-erfarne patienter bør ikke anvendes til patienter med en eller flere mutationer associeret med darunavirresistens (DRV-RAMs) eller hiv-1 RNA ≥100.000 kopier/ml eller CD4+-celletal <100 × 10 
Darunavir used in combination with cobicistat or low dose ritonavir once daily in ART-experienced patients should not be used in patients with one or more darunavir resistance associated mutations (DRV-RAMs) or HIV-1 RNA ≥ 100,000 copies/ml or CD4+ cell count < 100 cells x 10
Carbamazepin AUC ↑ 45% Carbamazepin Cmin ↑ 54% Carbamazepin Cmax ↑ 43% 
Carbamazepine 200 mg twice daily carbamazepine AUC ↑ 45% carbamazepine Cmin ↑ 54% carbamazepine Cmax ↑ 43% darunavir AUC ↔ darunavir Cmin ↓ 15%
Naloxegol til behandling af forstoppelse forårsaget af opioidbehandling 
NARCOTIC ANALGESICS / TREATMENT OF OPIOID DEPENDENCE
Immunrekonstitutionsinflammatorisk syndrom (IRIS) 
Immune reconstitution inflammatory syndrome
30 filmovertrukne tabletter: EU/1/17/1249/005 60 filmovertrukne tabletter: EU/1/17/1249/006 90 filmovertrukne tabletter: EU/1/17/1249/007 180 filmovertrukne tabletter: EU/1/17/1249/008 
30 film-coated tablets: EU/1/17/1249/005 60 film-coated tablets: EU/1/17/1249/006 90 film-coated tablets: EU/1/17/1249/007 180 film-coated tablets: EU/1/17/1249/008
Darunavir/ ritonavir 600/100 mg to gange dagligt N=296 
darunavir/ ritonavir 600/100 mg twice daily N=296
Darunavir Krka anvendt i kombination med cobicistat eller lavdosis ritonavir en gang daglig hos ART-erfarne patienter bør ikke anvendes til patienter med en eller flere mutationer associeret med darunavirresistens (DRV-RAMs) eller hiv-1 RNA ≥100.000 kopier/ml eller CD4+-celletal <100 × 10 
Darunavir Krka used in combination with cobicistat or low dose ritonavir once daily in ARTexperienced patients should not be used in patients with one or more darunavir resistance associated mutations (DRV-RAMs) or HIV-1 RNA ≥ 100,000 copies/ml or CD4+ cell count < 100 cells x 10
Darunavir Krka 400 mg og 800 mg tabletter anvendes kun til at sammensætte en dosis på 800 mg en gang dagligt. 
Darunavir Krka 400 milligram and 800 milligram tablets are only to be used to construct the once daily 800 milligram regimen.
Hvis parenteral midazolam coadministreres med boostet darunavir, skal det foregå på en intensivafdeling (ITA) eller i lignende rammer, der sikrer tæt klinisk monitorering og passende medicinsk håndtering i tilfælde af respirationsdepression og/eller 
If parenteral midazolam is coadministered with boosted darunavir, it should be done in an intensive care unit (ICU) or similar setting, which
Tredje trimester af graviditeten (n=12) 
Third trimester of pregnancy (n=12)
EU/1/17/1249/005 30 filmovertrukne tabletter EU/1/17/1249/006 60 filmovertrukne tabletter EU/1/17/1249/007 90 filmovertrukne tabletter EU/1/17/1249/008 180 filmovertrukne tabletter 
EU/1/17/1249/005 30 film-coated tablets EU/1/17/1249/006 60 film-coated tablets EU/1/17/1249/007 90 film-coated tablets EU/1/17/1249/008 180 film-coated tablets
Samtidig brug af lovastatin eller simvastatin og boostet darunavir er derfor kontraindiceret (se pkt. 
Concomitant use of boosted darunavir with lovastatin and simvastatin is therefore contraindicated (see section 4.3).
600 mg darunavir/100 mg ritonavir en gang dagligt 
600 mg darunavir/100 mg ritonavir once daily
Hvis der er behov for administration af rosuvastatin og boostet darunavir, anbefales det at starte med den lavest mulige dosis af rosuvastatin og optitrere til den ønskede kliniske effekt samtidig med overvågning af sikkerheden. 
When administration of rosuvastatin and boosted darunavir is required, it is recommended to start with the lowest possible dose of rosuvastatin and titrate up to the desired clinical effect while monitoring for safety.
EU/1/17/1249/001 30 filmovertrukne tabletter EU/1/17/1249/002 60 filmovertrukne tabletter EU/1/17/1249/003 90 filmovertrukne tabletter EU/1/17/1249/004 180 filmovertrukne tabletter 
EU/1/17/1249/001 30 film-coated tablets EU/1/17/1249/002 60 film-coated tablets EU/1/17/1249/003 90 film-coated tablets EU/1/17/1249/004 180 film-coated tablets
Genotype- og fænotypebestemmelse (hvor det er muligt) og behandlingsanamnese skal være vejledende for brugen af darunavir. 
Genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4.2, 4.4 and 5.1).
ved baseline Median CD4+celletals ændring fra baseline 
median CD4+ cell count change from baseline (x 10
Boostet darunavir forventes at øge plasmakoncentrationen af disse antineoplastika. 
Boosted darunavir is expected to increase these antineoplastic plasma concentrations.
Darunavir Krka 600 mg filmovertrukne tabletter darunavir 
Darunavir Krka 600 mg film-coated tablets darunavir
Samtidig brug af lovastatin eller simvastatin og darunavir administreret sammen med lavdosis ritonavir er derfor kontraindiceret (se pkt. 
Concomitant use of darunavir coadministered with low dose ritonavir with lovastatin and simvastatin is therefore contraindicated (see section
- Sildenafil, tadalafil, vardenafil(til behandling af impotens eller til behandling af en hjerte/lungesygdom kaldet pulmonal arteriel hypertension). 
Sildenafil, vardenafil, tadalafil (for erectile dysfunction or high blood pressure in the pulmonary circulation)
Hvis der er behov for administration af pravastatin og boostet darunavir, anbefales det at starte med den lavest mulige dosis af pravastatin og optitrere til den ønskede kliniske effekt samtidig med overvågning af sikkerheden. 
When administration of pravastatin and boosted darunavir is required, it is recommended to start with the lowest possible dose of pravastatin and titrate up to the desired clinical effect while monitoring for safety.
- 30 tabletter: 1 beholder med 30 filmovertrukne tabletter. 
3 bottles of 30 film-coated tablets.
Darunavir kan administreres sammen med lavdosis ritonavir og disse NRTI'er uden dosisjusteringer. 
Darunavir co-administered with low dose ritonavir can be used with these NRTIs without dose adjustment.
De farmakokinetiske egenskaber af darunavir i kombination med ritonavir to gange daglig hos 74 behandlingserfarne pædiatriske patienter i alderen 6 til 17 år med en legemsvægt på mindst 20 kg viste, at vægtbaserede doser af darunavir/ritonavir resulterede i en darunavireksponering, der var sammenlignelig med eksponeringen hos voksne, der fik darunavir/ritonavir 600/100 mg to gange daglig (se pkt. 
The pharmacokinetics of darunavir in combination with ritonavir taken twice daily in 74 treatmentexperienced paediatric patients, aged 6 to 17 years and weighing at least 20 kg, showed that the administered weight-based doses of darunavir/ritonavir resulted in darunavir exposure comparable to that in adults receiving darunavir/ritonavir 600/100 mg twice daily (see section 4.2).
fentanyl, oxycodon, tramadol (til behandling af smerter). 
Perphenazine,risperidone, thioridazine (to treat psychiatric conditions).
Darunavir kan administreres sammen med lavdosis ritonavir og atazanavir uden dosisjusteringer. 
Darunavir co-administered with low dose ritonavir and atazanavir can be used without dose adjustments.
Darunavir: sammenligning af darunavir/ritonavir 400/100 mg to gange daglig vs darunavir/ritonavir 400/100 mg i kombination med indinavir 800 mg to gange daglig. 
Darunavir: comparison of darunavir/ritonavir 400/100 mg twice daily vs. darunavir/ritonavir 400/100 mg in combination with indinavir 800 mg twice daily.
Hiv-1-RNA <50 kopier/ml Med hiv-1-RNA (kopier/ml) ved baseline 
With Baseline HIV-1 RNA (copies/ml)
Eksponering over for darunavir (og ritonavir) kan øges, når perikon seponeres. 
Darunavir exposure (and also ritonavir exposure) may increase on stopping St John's wort.
Koncentrationen af voriconazol kan øges eller nedsættes ved coadministration med darunavir coadministreret med cobicistat. 
(induction of CYP450 enzymes) Concentrations of voriconazole may increase or decrease when co-administered with darunavir co-administered with
Darunavir kan administreres sammen med lavdosis ritonavir og rilpivirin uden dosisjusteringer. 
Darunavir co-administered with low dose ritonavir and rilpivirine can be used without dose adjustments.
Darunavir: sammenligning af darunavir/ritonavir 400/100 mg to gang daglig vs darunavir/ritonavir 400/100 mg to gange daglig i kombination med atazanavir 300 mg en gang daglig. 
Darunavir: comparison of darunavir/ritonavir 400/100 mg twice daily vs. darunavir/ritonavir 400/100 mg twice daily in combination with atazanavir 300 mg once daily.
(CYP2D6- og/eller CYP3Ahæmning). 
(CYP2D6 and/or CYP3A inhibition).
De filmovertrukne tabletter (tabletter) er orange-brune, ovale, bikonvekse, indgraveret med mærket S2 på den ene side. 
What Darunavir Krka looks like and contents of the pack Film-coated tablets (tablets) are orangish brown, oval, biconvex, engraved with a mark S2 on one side.
(CYP2D6- og/eller CYP3Ahæmning) 
(CYP2D6 and/or CYP3A inhibition)
Darunavir kan administreres sammen med lavdosis ritonavir og didanosin uden dosisjusteringer. 
Darunavir co-administered with low dose ritonavir and didanosine can be used without dose adjustments.
Darunavir kan administreres sammen med lavdosis ritonavir og nevirapin uden dosisjusteringer. 
Darunavir co-administered with low dose ritonavir and nevirapine can be used without dose adjustments.
Der er dog rapporteret om svimmelhed hos nogle patienter under behandlingen med regimer, der indeholder darunavir, co-administreret med cobicistat eller lavdosis ritonavir. 
However, dizziness has been reported in some patients during treatment with regimens containing darunavir co-administered with cobicistat or low dose ritonavir and should be borne in mind when considering a patient's ability to drive or operate machinery (see section 4.8).
Darunavir/ritonavir 800/100 mg x 1 + OBR N=294 
Darunavir/ritonavir 800/100 mg once daily + OBR N=294
Darunavir/ ritonavir 600/100 mg 
darunavir/ ritonavir darunavir/ ritonavir 800/100 mg darunavir/ ritonavir darunavir/ ritonavir 600/100 mg
Dokumentationen for virkning af darunavir/ritonavir 800/100 mg en gang dagligt hos behandlingsnaive hiv-1-smittede patienter er baseret på 192 ugers-analysen af det randomiserede, kontrollerede, åbne fase III-studie ARTEMIS. 
The evidence of efficacy of darunavir/ritonavir 800/100 mg once daily is based on the analyses of 192 week data from the randomised, controlled, open-label Phase III trial ARTEMIS in antiretroviral treatment-naïve HIV-1 infected patients comparing darunavir/ritonavir 800/100 mg once daily with lopinavir/ritonavir 800/200 mg per day (given as a twice-daily or as a once-daily regimen).
Alfuzosin til behandling af forstørret blærehalskirtel (prostata) 
Alfuzosin to treat enlarged prostate
hiv-1-RNA <50 kopier/ml CD4+ procent ændring fra baseline CD4+-celletal gennemsnitlig ændring fra baseline 
HIV-1 RNA < 50 copies/ml CD4+ percent change from baseline CD4+ cell count mean change from baseline
Derfor er samtidig brug af kombinationsproduktet lopinavir/ritonavir og darunavir administreret sammen med lavdosis ritonavir kontraindiceret (se pkt. 
Hence, concomitant use of darunavir coadministered with low dose ritonavir and the combination product lopinavir/ritonavir is contraindicated (see section 4.3).
MIDLER MOD ANGINA PECTORIS/ANTIARYTMIKA Disopyramid 
ANTIANGINA/ANTIARRHYTHMIC
Clorazepat 
Clorazepate Diazepam
De farmakokinetiske egenskaber af darunavir i kombination med ritonavir en gang daglig hos 10 behandlingserfarne pædiatriske patienter i alderen 3 til <6 år med en legemsvægt på >14 kg til <20 kg viste, at vægtbaseret dosering resulterede i en darunavireksponering, der var sammenlignelig med eksponeringen hos voksne, der fik darunavir/ritonavir 800/100 mg en gang daglig (se pkt. 
The pharmacokinetics of darunavir in combination with ritonavir taken once daily in 10 treatmentexperienced paediatric patients, aged 3 to < 6 years and weighing at least 14 kg to < 20 kg, showed that weight-based dosages resulted in darunavir exposure that was comparable to that achieved in adults receiving darunavir/ritonavir 800/100 mg once daily (see section 4.2).
hiv-1-RNA <50 kopier/ml CD4+ procent ændring fra baseline 
HIV-1 RNA < 50 copies/ml CD4+ cell count mean change from baseline
(CYP3A- og/eller P-gphæmning) 
(CYP3A and/or P-gp inhibition)
400 mg en gang daglig didanosin AUC ↓ 9% didanosin Cmin ND didanosin Cmax ↓ 16% darunavir AUC ↔ darunavir Cmin ↔ darunavir Cmax ↔ 
400 mg once daily didanosine AUC ↓ 9% didanosine Cmin ND didanosine Cmax ↓ 16% darunavir AUC ↔ darunavir Cmin ↔ darunavir Cmax ↔
Darunavir forventes at øge plasmakoncentrationen af disse antipsykotika. 
Darunavir is expected to increase these antipsychotic plasma concentrations.